These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

688 related articles for article (PubMed ID: 30543451)

  • 1. Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series.
    Elms L; Shannon S; Hughes S; Lewis N
    J Altern Complement Med; 2019 Apr; 25(4):392-397. PubMed ID: 30543451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Cannabidiol (CBD) oil in the treatment of PTSD: Study design and rationale for a placebo-controlled randomized clinical trial.
    Telch MJ; Fischer CM; Zaizar ED; Rubin M; Papini S
    Contemp Clin Trials; 2022 Nov; 122():106933. PubMed ID: 36154908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder.
    Bolsoni LM; Crippa JAS; Hallak JEC; Guimarães FS; Zuardi AW
    Psychopharmacology (Berl); 2022 May; 239(5):1499-1507. PubMed ID: 35029706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review.
    Stanciu CN; Brunette MF; Teja N; Budney AJ
    Psychiatr Serv; 2021 Apr; 72(4):429-436. PubMed ID: 33530732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial.
    van der Flier FE; Kwee CMB; Cath DC; Batelaan NM; Groenink L; Duits P; van der Veen DC; van Balkom AJLM; Baas JMP
    BMC Psychiatry; 2019 Feb; 19(1):69. PubMed ID: 30760241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between cannabidiol and sertraline for the modulation of post-traumatic stress disorder-like behaviors and fear memory in mice.
    Han X; Song X; Song D; Xie G; Guo H; Wu N; Li J
    Psychopharmacology (Berl); 2022 May; 239(5):1605-1620. PubMed ID: 35396940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors.
    Campos AC; Ferreira FR; Guimarães FS
    J Psychiatr Res; 2012 Nov; 46(11):1501-10. PubMed ID: 22979992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabidiol in Anxiety and Sleep: A Large Case Series.
    Shannon S; Lewis N; Lee H; Hughes S
    Perm J; 2019; 23():18-041. PubMed ID: 30624194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of cannabinoids for the treatment of patients with post-traumatic stress disorder.
    Forsythe ML; Boileau AJ
    J Basic Clin Physiol Pharmacol; 2021 Mar; 33(2):121-132. PubMed ID: 33662194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabidiol ameliorates PTSD-like symptoms by inhibiting neuroinflammation through its action on CB2 receptors in the brain of male mice.
    Xie G; Gao X; Guo Q; Liang H; Yao L; Li W; Ma B; Wu N; Han X; Li J
    Brain Behav Immun; 2024 Jul; 119():945-964. PubMed ID: 38759736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report.
    Berlant J; van Kammen DP
    J Clin Psychiatry; 2002 Jan; 63(1):15-20. PubMed ID: 11838620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabidiol (CBD) use in psychiatric disorders: A systematic review.
    Bonaccorso S; Ricciardi A; Zangani C; Chiappini S; Schifano F
    Neurotoxicology; 2019 Sep; 74():282-298. PubMed ID: 31412258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoids and Mental Health, Part 2: The Search for Clinical Applications.
    Penn A
    J Psychosoc Nurs Ment Health Serv; 2019 Oct; 57(10):7-11. PubMed ID: 31573659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial.
    Bonn-Miller MO; Sisley S; Riggs P; Yazar-Klosinski B; Wang JB; Loflin MJE; Shechet B; Hennigan C; Matthews R; Emerson A; Doblin R
    PLoS One; 2021; 16(3):e0246990. PubMed ID: 33730032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
    Raskind MA; Thompson C; Petrie EC; Dobie DJ; Rein RJ; Hoff DJ; McFall ME; Peskind ER
    J Clin Psychiatry; 2002 Jul; 63(7):565-8. PubMed ID: 12143911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
    Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
    Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The alpha1-adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma posttraumatic stress disorder.
    Taylor F; Raskind MA
    J Clin Psychopharmacol; 2002 Feb; 22(1):82-5. PubMed ID: 11799347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans.
    Raskind MA; Peskind ER; Chow B; Harris C; Davis-Karim A; Holmes HA; Hart KL; McFall M; Mellman TA; Reist C; Romesser J; Rosenheck R; Shih MC; Stein MB; Swift R; Gleason T; Lu Y; Huang GD
    N Engl J Med; 2018 Feb; 378(6):507-517. PubMed ID: 29414272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.
    Mithoefer MC; Mithoefer AT; Feduccia AA; Jerome L; Wagner M; Wymer J; Holland J; Hamilton S; Yazar-Klosinski B; Emerson A; Doblin R
    Lancet Psychiatry; 2018 Jun; 5(6):486-497. PubMed ID: 29728331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.